8-K
Annovis Bio, Inc. (ANVS)
View as plain text
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of report (Dateof earliest event reported): September 25, 2025
ANNOVIS BIO, INC.
(Exact Name of Registrant as Specified in Charter)
| Delaware | 001-39202 | 26-2540421 |
|---|---|---|
| (State or Other Jurisdiction<br><br> <br>of Incorporation) | (Commission<br><br> <br>File Number) | (I.R.S. Employer<br><br> <br>Identification No.) |
101Lindenwood Drive**, Suite 225** Malvern , PA
19355
(Address of Principal Executive Offices, andZip Code)
(484) 875-3192
Registrant’s Telephone Number, IncludingArea Code
NotApplicable
(Former Name or Former Address, if Changed SinceLast Report)
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered |
|---|---|---|
| Common Stock, par value $0.0001 per share | ANVS | New York Stock Exchange |
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
| ¨ | Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|---|---|
| ¨ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| --- | --- |
| ¨ | Pre-commencement communication pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| --- | --- |
| ¨ | Pre-commencement communication pursuant to Rule 13e-4(c) under<br>the Exchange Act (17 CFR 240.13e-4(c)) |
| --- | --- |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).
Emerging growth company x
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. x
| Item 5.02. | Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements |
|---|
Effective September 25, 2025, Annovis Bio, Inc. (the “Company”) appointed Mark Guerin, age 57, as Chief Financial Officer of the Company. Prior to joining the Company, Mr. Guerin served as Chief Financial Officer of Onconova Therapeutics, now known as Traws Pharma, Inc. (Nasdaq: TRAW) from 2016 through February, 2025. Mr. Guerin has a bachelor’s degree in accounting from DeSales University and holds CPA, CMA, and CFM professional certifications. There are no transactions of the type required to be disclosed pursuant to Item 404(a) of Regulation S-K between the Company and Mr. Guerin.
In connection with Mr. Guerin’s appointment, Mr. Guerin will receive (i) an annual base salary of $450,000, (ii) an annual target bonus of 40%, (iii) stock options to purchase 200,000 shares of the Company’s common stock; (iv) six months severance pay; and (v) will be entitled to participate in employee benefit plans generally available to employees of the Company.
The Company issued a press release on September 25, 2025 announcing Mr. Guerin’s appointment, a copy of which is filed as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.
| Item 9.01 | Financial Statements and Exhibits |
|---|---|
| Exhibit Number | Description |
| --- | --- |
| 99.1 | Press Release dated September 25, 2025 |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| ANNOVIS BIO, INC. | |||
|---|---|---|---|
| Date: September 29, 2025 | By: | /s/ Maria Maccecchini | |
| Name: | Maria Maccecchini | ||
| Title: | President and Chief Executive Officer |
Exhibit 99.1
AnnovisAppoints Mark Guerin as Chief Financial Officer
MALVERN, Pa., Sept. 25, 2025 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) ("Annovis" or the “Company”), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson's disease (PD), today announced the appointment of Mark Guerin, CPA, CMA, CFM, as Chief Financial Officer (CFO) to help lead the Company through a pivotal phase as buntanetap continues to show promise in late-stage clinical development.
Mr. Guerin has extensive experience and a successful track record in managing financial operations within biopharma companies. In 2013, he joined Onconova Therapeutics, now known as Traws Pharma, Inc. (Nasdaq: TRAW), to augment the company’s financial reporting, forecasting, and internal controls following its IPO in July 2013, and was named its CFO in 2016. During his tenure as CFO, Onconova completed several critical financing transactions, including a rights offering, public offerings, registered direct offerings, and at-the-market offerings. Onconova merged with Trawsfynydd Therapeutics, Inc. in April 2024, with concurrent investments from OrbiMed and Torrey Pines, to form Traws Pharma, Inc. and to advance product candidates of both companies in virology and oncology. The company also completed an additional $20 million financing in December 2024.
Prior to joining Onconova, Mr. Guerin worked as an interim senior finance and accounting executive, facilitating post-acquisition integration activities of newly acquired private equity portfolio companies. He also served as Vice President of Finance and CFO at Cardiokine, Inc., overseeing its New Drug Application filing and subsequent sale of the company. Earlier in his career, Mr. Guerin was Director, Financial Reporting and Internal Controls at Barrier Therapeutics, Inc., supporting the company through its IPO and follow-on offering.
Mr. Guerin began his career at Coopers & Lybrand in Philadelphia. He has a bachelor’s degree in accounting from DeSales University and holds CPA, CMA, and CFM professional certifications.
“I am very excited to join the Annovis team at this critical juncture for the company and for patients with neurodegenerative diseases, as buntanetap has demonstrated efficacy in smaller trials and is on track to replicate that success in larger, registrational clinical studies,” commented Mark Guerin, CFO at Annovis. “I look forward to supporting the clinical success of buntanetap and to Annovis delivering a therapeutic solution for patients who need it most.”
AboutAnnovis
Headquartered in Malvern, Pennsylvania, Annovis is dedicated to addressing neurodegeneration in diseases such as Alzheimer’s disease (AD) and Parkinson’s disease (PD). The Company is committed to developing innovative therapies that improve patient outcomes and quality of life. For more information, visit www.annovisbio.com and follow us on LinkedIn, YouTube, and X.
InvestorAlerts
Interested investors and shareholders are encouraged to sign up for press releases and industry updates by registering for email alerts at https://www.annovisbio.com/email-alerts.
Forward-LookingStatements
This press release contains forward-looking statements under the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended. Actual results may differ due to various risks and uncertainties, including those outlined in the Company’s SEC filings under “Risk Factors” in its Annual Report on Form 10-K and Quarterly Reports on Form 10-Q. The Company undertakes no obligation to update forward-looking statements except as required by law.
ContactInformation:
Annovis Bio Inc.
101 Lindenwood Drive
Suite 225
Malvern, PA 19355
www.annovisbio.com
InvestorContact:
Alexander Morin, Ph.D.
Director, Strategic Communications
Annovis Bio
ir@annovisbio.com